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Ewing sarcoma is an aggressive bone malignancy that affect children and young adults.
Ewing sarcoma is the second most common primary bone malignancy in pediatric
patients. Although significant progress has been made in the treatment of Ewing
sarcoma since it was first described in the 1920s, in the last decade survival rates
have remained unacceptably invariable, thus pointing to the need for new approaches
centered in the molecular basis of the disease. Ewing sarcoma driving mutation,
EWS–FLI1, which results from a chromosomal translocation, encodes an aberrant
transcription factor. Since its first characterization in 1990s, many molecular targets have
been described to be regulated by this chimeric transcription factor. Their contribution to
orchestrate Ewing sarcoma phenotype has been reported over the last decades. In this
work, we will focus on the description of a selection of EWS/FLI1 targets, their functional
role, and their potential clinical relevance. We will also discuss their role in other types
of cancer as well as the need for further studies to be performed in order to achieve a
broader understanding of their particular contribution to Ewing sarcoma development.
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Introduction
Ewing sarcoma is a rare tumor that arisesmainly in the bones of children and adolescents.Despite the
improvements in treatment achieved during the last decades, survival rates have remained unaccept-
ably low, even in patients with localized disease, since a great proportion of Ewing sarcoma tumors
are refractory to conventional treatment and relapses are frequent (1). In addition, approximately
25% of cases present disseminated disease at diagnosis, which have a very poor prognosis (2). Thus,
there is an urgent need for new targeted therapies that may offer a higher efficiency and less adverse
effects than the conventional chemo/radiotherapies that are used nowadays.
In this sense, understanding the molecular basis of Ewing sarcoma pathogenesis provides key
information that may help to design new targeted biological therapies. Ewing sarcomas are char-
acterized by chromosomal translocations that fuse the EWSR1 gene to some members of the ETS
family of transcription factors (3), being FLI1 the most frequently implicated [t(11;22)(q24;q12)]
(4). The EWS/FLI1 fusion protein is an aberrant transcription factor that is essential for Ewing
tumor development, since it regulates the expression of multiple target genes and governs the
oncogenic processes that lead to malignant transformation of a yet undefined cancer precursor
cell. Provided that the oncogenic properties of EWS/FLI1 rely on its capability to induce or repress
specific target genes, these target genes can likewise offer interesting opportunities to identify new
targeted therapies.
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In the past years, an important effort to identify EWS/FLI1
genes functionally relevant for Ewing sarcoma pathogenesis has
been carried out. As a consequence, many genes that play an
important role in Ewing sarcoma have been identified (5–17).
This has revealed some keymolecular pathways involved in Ewing
pathogenesis, and more importantly it has provided new molecu-
lar targets.
A comprehensive discussion of all EWS/FLI1 target genes iden-
tified to date and their implications in targeted therapy is beyond
the scope of this review. Thus, here we have focused on a selection
of six EWS/FLI1 target genes that, in our opinion, can represent
attractive opportunities for future studies that may lead to dis-
covering new therapeutic approaches. This selection takes into
account the presence of significant data – in Ewing or in other
systems – regarding potential therapeutic applications. Four genes
encode for transcriptional regulators while the other two encode
for secreted proteins.
Transcriptional Regulators
DAX-1 (NR0B1)
DAX-1 is a gene that belongs to the super family of nuclear
receptors (official name NR0B1, standing for Nuclear Receptor
Subfamily 0, Group B, Member 1). Nuclear receptors are tran-
scription factors that undergo activation upon binding of small
ligands such as retinoic acid or steroids. However, there is no
known ligand for DAX-1, and thus we refer to it as an orphan
nuclear receptor. Germline mutations in this gene are the cause
of dosage-sensitive sex reversal (DSS) in XY individuals and
adrenal hypoplasia congenital (AHC), which is characterized by
adrenal insufficiency, and hypogonadotropic hypogonadism in
males. DAX-1 is a master regulator of steroidogenesis that neg-
atively regulates the steroidogenic factor 1 (SF1), an important
transcriptional activator of genes involved in steroid hormone
production (18, 19). In addition, DAX-1 plays an important role in
several biological processes such as osteoblast differentiation (20),
ion homeostasis and transport, lipid transport, or skeletal develop-
ment (21) among others. More recently, DAX-1 has been involved
in the maintenance of mouse embryonic stem cell pluripotency
through regulation of stem cell genes like Oct-3/4 (22–24).
Given that DAX-1 function is mainly linked to steroidogenesis,
it was surprising to find this gene associated to Ewing sarcoma,
a tumor with no known relationship with steroidogenic tissues.
Gene expression profiles performed in two heterologous cellmod-
els ectopically expressing EWS/FLI1 (HEK293 and HeLa cells)
demonstrated that DAX-1 was specifically induced by EWS/FLI1,
but not by wildtype FLI1 (25). In addition, it was shown that
DAX-1 was highly expressed in Ewing sarcoma cell lines and
tumors, while it was not expressed in other pediatric tumors
such as rhabdomyosarcoma or neuroblastoma. Finally, DAX-1
expression was demonstrated to depend on EWS/FLI1 expression
in the A673 Ewing sarcoma cell line upon EWS/FLI1 knockdown.
An independent study showed similar findings, confirming that
DAX-1 is a target of the EWS/FLI1 oncoprotein (26).
Several functional studies have demonstrated that DAX-1 plays
a critical role in Ewing sarcoma pathogenesis: DAX-1 knockdown
impairs Ewing sarcoma cell proliferation, G1 cell arrest induction,
inhibits anchorage independent growth of colonies in soft agar,
and drastically inhibits growth of xenotransplanted tumor cells
in immunodeficient mice (9, 25, 26). These results are highly
consistent since they were obtained in independent laboratories,
using several Ewing sarcoma cell lines (TC71, EWS502, andA673)
and different gene knockdown technologies (i.e., transient retro-
virus infection or inducible expression of EWS/FLI1 shRNAs).
Interestingly, characterization of the gene expression profile reg-
ulated by DAX-1 in Ewing sarcoma cell lines has also provided
interesting findings regarding the function of DAX-1 in Ewing
sarcoma. These studies showed that a significant percentage of
the genes regulated by EWS/FLI1 in Ewing sarcoma cells are
also under the control of DAX-1, reinforcing the importance of
DAX-1 in Ewing sarcoma pathogenesis. In fact, two independent
works demonstrated that EWS/FLI1 and DAX-1 transcriptional
profiles share a significant number of genes, suggesting that DAX-
1 not only contributes to the EWS/FLI1 transcriptional signa-
ture but also that there is a hierarchy controlled by EWS/FLI1
and in which some genes, such as DAX-1, can play a more
prominent role (9, 27). The study of the mechanism through
which EWS/FLI1 upregulates DAX-1 expression in Ewing sar-
coma cells revealed an unexpected finding: EWS/FLI1 directly
interacts with DAX-1 promoter through binding to a GGAA-
rich sequence (9, 28). This motif resulted to be a polymor-
phic microsatellite located in the DAX-1 promoter. It has been
demonstrated that EWS/FLI1 binds similar sequences located
in the promoters of other EWS/FLI1 target genes, indicating
that this mechanism of gene transcriptional activation is fre-
quently used by EWS/FLI1 to regulate the expression of some
oncogenic genes (28) [i.e., Caveolin-1 (CAV1) (7), glutathione S-
transferase M4 (GSTM4) (29), FCGRT (Fc fragment of IgG, recep-
tor, transporter, alpha), FVT1/KDSR (3-ketodihydrosphingosine
reductase)or ABHD6 (Abhydrolase Domain-Containing Protein)
(30)]. The fact that DAX-1 expression is regulated through a
polymorphic repeat of the GGAA motif raised the question if
the number of repeats could be somehow linked to the level of
DAX-1 expression and, as a consequence, to themalignant pheno-
type of Ewing sarcoma. Several biochemical studies demonstrated
a relationship between the number of GGAA repeats and the
degree of promoter activation, indicating that it was necessary
a minimum of nine repeats to obtain a response to EWS/FLI1
(30). However, the attempts to establish a relationship between
the length of themicrosatellite located inDAX-1 promoter and the
clinical prognosis have raised contradictory results. For instance,
GGAA microsatellites were longer in African populations, which
are known to have a lower incidence of Ewing sarcoma but a
worse overall survival when compared to European populations
(31, 32). Conversely, in another study based on 112 patients, the
length of theDAX-1microsatellite showedno influence on clinical
outcomes (33).
Taking into account all these results, DAX-1 can be considered
as one of the most relevant EWS/FLI1 gene targets. The fact
that DAX-1 expression results essential for EWS/FLI1-mediated
oncogenesis opens the possibility, at least in theory, to consider
DAX-1 targeting as an attractive therapeutic approach in Ewing
sarcoma. As a consequence, a more profound understanding
of the functions that DAX-1 exerts in Ewing sarcoma and the
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molecular mechanism involved in them can provide new clues on
how to interfere with its expression or function in this cancer (34).
DAX-1 is located in the nucleus of Ewing sarcoma cells, where
it presumably interacts with other transcription factors and cofac-
tors to regulate downstream target genes that are important for
oncogenesis. Interestingly, a combination of biochemical and
gene expression profile experiments leads to the observation
that EWS/FLI1 and DAX-1 interact physically. Specifically, it
was found that both the amino- and carboxyl-termini of DAX-
1 interacted with EWS/FLI1 (27). This result opens the attractive
possibility that interfering EWS/FLI1-DAX-1 interaction could
lead to new therapeutic opportunities. To go forward in this line
of work, it would be necessary to finely map the regions involved
in this interaction in order to design small molecules with the
ability to block it. Since DAX-1 and EWS/FLI1 interaction could
be necessary for full EWS/FLI1-mediated oncogenesis, disturbing
it could be therapeutically valuable.
DAX-1 has been shown to interact in different cellular contexts
with a variety of transcriptional regulators, mainly corepressors.
For example, DAX-1 interacts with Alien corepressor through its
silencing domain and this interaction has been shown to be impor-
tant for AHC pathogenesis (35). DAX-1 has also been shown to
interact directly with the androgen receptor, NR3C4, inhibiting
its activation (36) and other partners such as NR5A1 (37) and
ESRRγ (38). To date, a systematic analysis of the protein–protein
interactions in which DAX-1 is involved in Ewing sarcoma cells
and the role that these interactions can play in Ewing sarcoma
pathogenesis has not been carried out. Experiments focused on
identifying and characterizing these interactions could provide
clues for designing synthetic drugs to target them. On the other
hand, it has been shown that DAX-1 C-terminal domain contains
a potent transcriptional repressor domain that, when altered by
mutations in AHC patients, impairs its nuclear localization, and
therefore its transcriptional activity (39), suggesting that there
is a potential field for developing drugs to modulate DAX-1
subcellular localization and consequently its function.
As with any new drug, the possible side effects of a new
therapeutic approach must be also taken into consideration. For
instance, prolonged DAX-1 blockage may lead to disequilibrium
in steroid hormones production, which could lead to Cushing-like
syndrome (40). These hypothetical complications, compared with
the severity of Ewing sarcoma itself, would be perfectly assum-
able. One theoretical advantage of using therapeutic approaches
targeting DAX-1 is that this gene is only expressed in a limited
number of tissues, mainly in adrenal gland and testis, and prob-
ably DAX-1 targeting will only affect these organs. In summary,
although there are currently no drugs able to target DAX-1 and
block its function, studies intended to understand its structure, its
mechanism of interaction with other transcriptional (co)factors,
and the identification of other protein–protein interactions in the
Ewing sarcoma context could provide new insights to design new
therapeutic molecules (Figure 1).
GLI1
GLI1 (Glioma-Associated Oncogene Homolog 1) is a transcription
factor belonging to the Kruper family of zinc finger proteins. GLI1
is a component of the canonical Hedgehog pathway: extracellular
Sonic Hedgehog (Shh) binds to the PTCH receptor causing the
liberation of Smooth (SMO) from the PTCH-SMO complex.
Subsequently, activated SMO releases GLI1 from the complex
that it forms with Suppressor of Fused (SUFU), which permits
GLI1 nuclear translocation where it regulates gene transcription
of genes involved in normal cell growth and differentiation such
as the embryonic pattern formation (41). Although this pathway
is mainly active during embryogenesis, it remains active in some
adult tissues, where it is involved in homeostasis and stem-cell
maintenance (42, 43).
Zwerner et al. described an association between EWS/FLI1 and
GLI1 in Ewing sarcoma cells. They showed that NIH3T3 cells
expressing EWS/FLI1 presented the expected malignant pheno-
type concomitantly with augmented levels of GLI1 (44). More-
over, when GLI1 expression was knocked-down by RNA inter-
ference, the transformed phenotype was reduced (demonstrated
by a decrease in the anchorage independent growth) indicating
that GLI1 plays an important role in the maintenance of the
malignant phenotype induced by EWS/FLI1. Interestingly, SUFU
overexpression, which is expected to inhibit GLI1, also produced
similar effects in NIH3T3 cells. In TC32 Ewing sarcoma cells,
EWS/FLI1 knocking down using RNA interference produced a
reduction in GLI1 expression levels. Also, ChIP studies demon-
strated that GLI1 is a direct target of EWS/FLI1 (45). Moreover,
when a shRNA against GLI1 was used in the Ewing sarcoma cell
line TC32, the transformedphenotypewas inhibited (measured by
reduction in anchorage independent growth) (44). Interestingly,
and in contrast with what it is usually observed in other types
of cancer, GLI1 deregulation in Ewing sarcoma is independent of
Shh since its activation did not produce phenotypic changes nor
did a pharmacological blockage of SMO using cyclopamine (an
inhibitor of Shh signaling by direct binding to SMO) (45).
Subsequently Joo et al. (46) showed that Ewing primary tumors
expressed high levels of GLI1. These authors also confirmed using
RNAi that the expression of GLI1 in Ewing sarcoma cells (TC71)
is dependent on EWS/FLI1 and that GLI1 expression was relevant
for the maintenance of the transformed phenotype. Strikingly,
re-analysis of gene expression profiles showed that genes that
were traditionally thought to be transcriptionally modulated by
EWS/FLI1, such as NKX2.2, Patched (PTCH) or GAS1, were
indeed dependent on GLI1 expression, meaning that the gene
expression network regulated by EWS/FLI1 holds a hierarchy in
which GLI1 has a prominent role.
Deregulation of the Shh–GLI1 pathway has been showed to
lead to tumorigenesis and aggressive phenotypes (progression,
metastasis and therapeutic resistance) of numerous cancer types
such as basal cell carcinomas (47), colorectal carcinoma (48),
breast cancer (49), and bone and soft tissue sarcomas (50).
Given the importance of Shh–GLI1 pathway in cancer, some
therapeutic approaches, focused on the blocking of this pathway,
have been developed over the years. One of these strategies con-
sisted in searching for small molecule inhibitors of the pathway.
Thus, Shh–GLI1 pathway inhibitors, such as cyclopamine, have
been successfully tested in some cancer types such asmedulloblas-
toma (51), pancreatic adenocarcinoma (52), small-cell lung can-
cer (SCLC) (53), gastric adenocarcinomas (54), and esophageal
cancer (55).
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FIGURE 1 | DAX-1 and therapeutic opportunities in Ewing sarcoma.
DAX-1 expression is upregulated by EWS/FLI1 in Ewing sarcoma cells through a
direct interaction with a polymorphic GGAA microsatellite located in the DAX-1
promoter. Since DAX-1 expression is essential for EWS/FLI1-mediated
oncogenesis, it is still necessary to ascertain if it interacts with other
transcription factors (1) and/or co-repressors (2) in the nucleus of Ewing
sarcoma cells. This could open new therapeutic approaches for designing
molecules to target these interactions. Potential therapeutic targets may be
molecules that prevent EWS/FLI1 binding to the GGAA-rich motifs in DAX-1
promoter (3) or drugs directed toward the EWS/FLI1-DAX-1 interaction, whose
concurrence could be necessary to regulate the expression of certain genes (4).
Finally, DAX-1 C-terminal domain can impair DAX-1 nuclear localization when
altered so it could be potentially targeted to modulate its subcellular localization
and thus its function (5).
The fact that GLI1 expression is constitutively induced by
EWS/FLI1 in Ewing sarcoma suggests that drugs acting upstream
GLI1 will be ineffective in blocking this pathway in this cancer.
In agreement with this, cyclopamine treatment of Ewing sarcoma
cells would have no effect on the malignant characteristics of
Ewing sarcoma cells. For this reason, efforts should be directed
toward developing and studying drugs targeting GLI1 expression
or function directly. In this sense, arsenic trioxide (ATO), an
old drug recently reintroduced in the repertoire of anticancer
drugs, has been found to inhibit cell growth by targeting GLI
proteins (56). In the specific case of Ewing sarcoma, ATO pre-
sented cytotoxicity in cell lines with upregulated GLI1 expres-
sion (TC-71, SKES and A4573), and curbed xenograft growth
performed with TC-71 cells (57). ATO was also found to inhibit
Ewing cells (RDES and A673) migration and invasiveness, thus
implying that it could also have a therapeutic effect on metastasis
(58). Of note, ATO has already been tested in combination with
other chemotherapeutic drugs (etoposide and paclitaxel) in a
preliminary study that included Ewing sarcoma and metastatic
osteosarcoma patients where tumor growth was controlled in 75%
of cases (59). However, since Ewing sarcoma is mainly a pediatric
cancer, it is necessary to further investigate its effects and to be
prudent when designing clinical studies given the roles of the
Shh–GLI1 pathway in development.
Finally, it has been described a correlation between GLI1
expression levels and/or prognosis and recurrence in some cancer
types. For instance, in a study comprising 25 clinical samples
of colorectal carcinoma, Shh expression was found upregulated
and, interestingly, when GLI1 expression was analyzed by in situ
hybridization, it was mainly found in the malignant crypts of
adenocarcinomas (48). Also, it has been described a positive
correlation between GLI1 expression and tumor grade and/or
lymph node status, pointing to a role of GLI1 in metastasis. Some
examples are breast cancer, where high GLI1 expressionmeasured
in a TMA containing 204 tumor samples was associated with
poor prognosis and progressive stages of disease (49) or bone
and soft tissue sarcomas, where higher GLI1 expression corre-
lated with more aggressive outcomes (50). In the specific case of
Ewing sarcoma, these studies remain to be performed, especially
considering that a deeper knowledge on this field could lead to
a more efficient patient stratification that could help improve
treatment.
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FIGURE 2 | GLI1 and therapeutic opportunities in Ewing sarcoma. GLI1
is an upregulated direct target gene of EWS/FLI1 in Ewing sarcoma cells.
Functional studies have demonstrated that GLI1 expression is relevant for the
maintenance of the transformed phenotype in this system. Moreover, some
genes transcriptionally modulated by EWS/FLI1 depend on GLI1 expression,
including NKX2.2, PATCH, and GAS1 (1). Therapeutic opportunities may
include the use of molecules capable of inhibiting GLI1-mediated
transcription, such as arsenic trioxide (As2O3) (2). Also it may be interesting to
ascertain the possible link between GLI1 expression pattern and prognosis in
Ewing sarcoma given that this correlation between GLI1 expression and bad
prognosis exists in other tumor types (breast cancer and bone and soft tissue
sarcomas) (3).
There is still an urgent need for further functional studies that
can ascertain the exact role of this pathway in Ewing sarcoma
development and progression. These studies could help to syn-
thesize new compounds or small molecules that could target GLI1
with better efficacies either alone or in combination with normal
chemotherapeutic treatments (Figure 2).
Forkhead Box (FOX) of Transcription Factors
Forkhead box proteins are an extensive family of transcriptional
regulators that share a common DNA binding domain (the
forkhead domain). There are 19 subgroups (FOXA to FOXS)
organized on the basis of sequence homology inside and out-
side the forkhead domain. FOX proteins regulate gene networks
that are involved in cell cycle progression, proliferation, differ-
entiation, metabolism, senescence, survival, or apoptosis (60).
Thus, it is not strange that these transcription factors have been
shown to have roles in cancer. Interestingly, some members of
this family have been shown to act as tumor suppressor genes,
while others have been shown to be pro-oncogenic. Examples
of both of these opposed functions have been identified in
Ewing sarcoma.
The FOXOsubgroup (consisting of FOXO1, FOXO3A, FOXO4,
and FOXO6) are key negative regulators of cell proliferation and
survival. They induce cell cycle arrest at G1 (61) and apopto-
sis and DNA repair (62). They are thus considered bona fide
tumor suppressors. For example, in prostate cancer, FOXO1 is
found transcriptionally downregulated and the induction of its
expression in prostate cancer cells inhibits cell proliferation and
survival (63). In addition, FOXO1 has been also shown to regulate
other hallmarks of cancer such as angiogenesis. Thus, FOXO1
loss of function increases blood vessel formation and promotes
endothelial cell proliferation and migration (64, 65).
FOXOs transcriptional activity is regulated by changes in their
cellular localization, which is mediated by protein kinases such
as the serum/glucocorticoid kinase (SGK) and the protein kinase
B (AKT) [reviewed in Ref. (66)]. These transcription factors can
also undergo different post-translational modifications that reg-
ulate their activity including deacetylation mediated by Sirt1 and
ubiquitination mediated by Skp2 and Mdm2 (67).
EWS/FLI1 binds to the FOXO1 promoter and represses its
expression in Ewing sarcoma cells (68). In accordance with this,
FOXO1 is expressed at lower levels in primary Ewing sarcoma
as compared to other tissues (16). Induction of FOXO1 in two
Ewing sarcoma cells (A673 and SKNMC) resulted in impaired
cell proliferation and reduced soft agar colony formation capa-
bility, confirming that FOXO1 is a tumor suppressor in Ewing
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sarcoma and that its inhibition is important for Ewing sarcoma
growth. Interestingly, EWS/FLI1 also indirectly regulates the sub-
cellular localization of FOXO1 and thus controls its transcrip-
tional activity. CDK2- (which is upregulated by EWS/FLI1 and
acts as a negative regulator of FOXO1 transcriptional activ-
ity) and AKT-mediated phosphorylation of FOXO1 cooperate
to block its transport to the nucleus thus inhibiting its tran-
scriptional activity. These findings demonstrate that EWS/FLI1
blocks FOXO1 activity at several different levels in Ewing sar-
coma cells.
Since FOXO1 acts as a tumor suppressor in Ewing sarcoma,
a valuable therapeutic approach can consist in the reactivation
of FOXO1 activity. In this regard, methylseleninic acid (MSA),
a chemical compound previously shown to reactivate FOXO1 in
prostate cancer, was tested in Ewing sarcoma cells (69). Treat-
ment of Ewing sarcoma cells with MSA induced FOXO1 expres-
sion in a concentration-dependent manner, which correlated
with apoptotic-mediated cell death. This effect was mediated at
least in part by FOXO1, since the knockdown of endogenously
induced FOXO1 significantly reduced the apoptotic effect of
MSA. Notably, administration of MSA in an orthotopic mouse
xenotransplantation model significantly reduced tumor growth,
suggesting that MSA could be a potential therapeutic approach
in Ewing sarcoma. However, it should be taken into account
that high concentrations of selenium are usually associated with
intoxication, which can make this approach problematic. This
means that any potential application of MSA should use effective,
low doses, which in combination with conventional chemother-
apeutic drugs can reach the desired anti-tumoral effects. Par-
ticularly, MSA has already been proved to synergize well with
some chemotherapeutic drugs that are frequently used in Ewing
sarcoma, such as etoposide or doxorubicin (70) (Figure 3). Since
reactivation of FOXO1 in Ewing sarcoma cells has shown to be
effective both in vitro and in vivo, more studies are necessary to
understand the mechanism involved in the regulation of FOXO1
expression and its transcriptional activity in order to identify new
therapeutic targets.
FOXM1 is another member of the FOX family of transcrip-
tion factors that contrary to FOXO displays a pro-oncogenic
role in cancer. In fact, FOXM1 is one of the most commonly
overexpressed genes in solid tumors (71). Initially, FOXM1 was
described as a proliferation-specific mammalian transcription
factor, expressed in proliferating cells but not in quiescent or
terminally differentiated cells. In addition to this, and over the
years, FOXM1has also been implicated in cellmigration, invasion,
angiogenesis, metastasis, or oxidative stress (72).
Christensen et al. showed that EWS/FLI1 upregulated the lev-
els of FOXM1 in four Ewing sarcoma cell lines, although the
mechanism appeared to be indirect (17). In agreement with this,
FOXM1 is expressed at high levels in Ewing sarcoma cell lines and
primary tumors. In order to characterize the relevance of FOXM1
in Ewing sarcoma pathogenesis, the authors performed FOXM1
FIGURE 3 | FOXO1 and therapeutic opportunities in Ewing sarcoma.
FOXO1 is a direct target gene of EWS/FLI1 and its expression is repressed by
EWS/FLI1 in Ewing sarcoma cells. Functional studies have shown that FOXO1
acts as a tumor suppressor in the Ewing sarcoma cell context. Therapeutically,
Methane Sulfonic Acid (MSA) may be used as a potential treatment in synergy
with other chemotherapeutic agents such as doxorubicin or etoposide.
However, its mechanism of action in Ewing sarcoma is still unknown (1). Also
there is still a need to clarify the FOXO1 activities mediated by kinases such as
CDK2 and AKT (2) together with the regulation of its subcellular localization (3),
and to determine if they may be mediated by EWS/FLI1.
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knockdown experiments demonstrating that FOXM1 downregu-
lation correlates with a significant reduction in anchorage inde-
pendent growth.
Interestingly, pharmacological approaches addressed to reduce
FOXM1 levels have also been tested in Ewing sarcoma cells with
notable results. Thiostrepton, a thiazole antibiotic, has been shown
to act as a proteosomal inhibitor (73) and also to physically
interact with FOXM1 consequently inhibiting FOXM1 binding
to target promoters (74). FOXM1 expression was inhibited by
treatment with thiostrepton, which paralleled with an increase in
apoptosis in a variety of Ewing sarcoma cell lines (17). Thiostrep-
ton was also shown to inhibit tumor growth in mouse xenograft
models (75). Strikingly, in this work, thiostrepton was able to con-
comitantly inhibit the expression of EWS/FLI1 both atmRNA and
protein levels in three Ewing cell lines and in tumors derived from
thiostrepton-treated mouse xenograft models (75). Although the
mechanism by which thiostrepton promotes EWS/FLI1 down-
regulation was not characterized, these results suggest that this
drug may show greater efficacy in Ewing sarcoma tumors in
comparison to other tumors.
As stated above, FOXM1 is frequently overexpressed in cancer
and takes part in each hallmark of cancer. Consequently it has
been argued that targeting FOXM1 could provide an opportunity
to treat cancer. It has also been proposed that FOXM1 could be
the “Achilles heel” of cancer (76). Taken together, these findings
suggest that targeting FOXM1 may be also an opportunity for
Ewing sarcoma treatment (Figure 4).
Secreted Proteins
Cholecystokinin
Cholecystokinin (CCK) is a neuropeptide that displays a diver-
sity of functions in the organism. It was originally discovered
in the gastrointestinal tract, where it mainly regulates pancreatic
secretion of digestive enzymes. In addition, CCK is one of the
most abundant and widely distributed neuropeptides in the brain,
where it modulates intrinsic neuronal excitability and synaptic
transmission. CCK is secreted as a prohormone (proCCK) that
subsequently undergoes post-translational processing (tyrosine
sulfatation, endoproteolytic cleavage, basic residue removal, and
C-terminal amidation), resulting in the production of CCK bio-
logically active forms, mainly CCK8 (77).
More than two decades ago, CCK was found to be specif-
ically expressed in a group of human cancer cell lines that
included Ewing sarcoma, neuroepithelioma and leiomyosarco-
mas, as opposed to other tumor cell lines derived from osteogenic
sarcomas, rhabdomyosarcoma, melanoma, and SCLC (78). Sub-
sequent studies carried out in tumor specimens confirmed that
CCK expression was high in the majority of Ewing sarco-
mas, whereas in other tumors, CCK-positive cases ranged from
50% in leiomyosarcomas to 0% in medulloblastomas, central
primitive neuroectodermal tumors (PNET), neuroblastomas, and
rhabdomyosarcomas (79). In agreement with this, a later study
demonstrated the presence of proCCK in the supernatant of Ewing
sarcoma cell lines in culture, indicating that CCK is actively
FIGURE 4 | FOXM1 and therapeutic opportunities in Ewing
sarcoma. FOXM1 is upregulated by EWS/FLI1 in Ewing sarcoma cells,
although it is unknown whether its regulation is direct or indirect (1).
Thiostrepton (TS) blocks FOXM1 in Ewing sarcoma cells decreasing
their neoplastic features (2). However, the exact mechanism underlying
these effects remains unexplained. In addition, FOXM1 has been shown
to be capable of inhibiting EWS/FLI1 probably by an indirect
mechanism that still needs to be clarified (3). Also TS has been proved
to inhibit EWS/FLI1 expression in Ewing cells, although the exact
mechanism is still unknown (4).
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secreted by Ewing sarcoma cells (80). Interestingly, these authors
found high concentrations of proCCK in the plasma of Ewing
sarcoma patients but not in patients with other pediatric tumors
such as osteosarcoma, neuroblastoma, nephroblastoma, rhab-
domyosarcoma or synovial sarcoma. Interestingly, the levels of
proCCK in plasma correlated with tumor size and recurrence. In
addition, proCCK levels in plasma decreased after chemother-
apeutic treatment, concurrently with a reduction in tumor size
and in one patient, proCCK levels increased again correlating
with tumor recurrence. All together, these results consistently
demonstrate that CCK is expressed and secreted at high levels in
Ewing sarcoma.
The first data demonstrating a relationship between CCK
expression and EWS/FLI1 came from studies performed in het-
erologous systems: ectopic expression of EWS/FLI1 in the RD
rhabdomyosarcoma cell line and in HeLa cells (81) upregulated
CCK mRNA levels. This relationship between EWS/FLI1 and
CCK was confirmed in Ewing sarcoma cells. Thus, EWS/FLI1
knockdown in A673 and SK-PN-DW Ewing sarcoma cell lines
downregulated CCK mRNA levels, demonstrating that CCK
expression is dependent on EWS/FLI1. Whether CCK is a direct
or indirect target of EWS/FLI1 is a question that yet remains to
be determined (8). Regarding the functional relevance of CCK in
Ewing sarcoma, it was shown that downregulation of CCK using
a shRNA inducible system, inhibited cell proliferation in vitro
and tumor growth in vivo. In addition, CCK-rich culture media
or exogenous CCK-8 was able to stimulate Ewing sarcoma cell
proliferation in vitro, suggesting that CCK is an autocrine growth
factor in Ewing sarcoma cells (8, 82). Unfortunately, to date no
studies have been carried out to decipher the mechanisms that
underlie this effect in Ewing sarcoma.
The fact that CCK is highly expressed in Ewing sarcoma and
the observation that it can act as an autocrine growth factor in vivo
suggest that blocking this autocrine loop, for example, using CCK
receptor antagonists, could be of therapeutic interest. CCK and
gastrin (a closely related hormone) share two G-protein coupled
receptors, named CCKAR and CCKBR that trigger numerous
pathways that transmit the mitogenic signal to the nucleus to
promote cell proliferation. Whereas CCKA receptors are spe-
cific for CCK, CCKB receptors can bind CCK and gastrin with
high affinity. Expression of CCK receptors in Ewing sarcoma has
been scantly studied with contradictory results. Schaer and Reubi
reported a lack of CCK receptors expression in a collection of
11 Ewing sarcoma tumors using autoradiography and 32P-labeled
CCK-8 as a probe (79). However, more recently it was demon-
strated the existence of both CCKA and B receptors mRNA in two
Ewing sarcoma cell lines (A673 and SK-PN-DW) and a cohort of
ten primary tumors (8).
Treatment of Ewing sarcoma cell lines with devazepide, a spe-
cific CCKAR antagonist derived from the benzodiazepine family,
induced apoptosis in vitro and significantly reduced the tumor
growth in a mouse xenograft model (83). However, these effects
were observed with IC50 values 10,000-fold higher that those
necessary to efficiently block the binding of CCK to its CCKA
receptor. In addition, one specific antagonist of the CCKB recep-
tor (L365 260) had no effect on Ewing sarcoma cell proliferation
or viability (83). These results suggest that in Ewing sarcoma cells
there could be an alternative mechanism of action that could
involve CCK receptors other than the standard ones, and open
the possibility that cell proliferation induced by CCK in Ewing
sarcoma cell lines could also be mediated through a yet unknown
mechanism.
Regardless of the possibility to block CCK-induced prolifera-
tion with specific antagonists, the expression of CCK receptors in
tumors can itself be therapeutically useful. In this sense, a model
of metastatic medullary thyroid cancer has been successfully used
to evaluate the diagnostic and therapeutic potential of radiola-
beled gastrin directed to target CCKB receptor-expressing tumors
in vivo (84). Using this approach, a collection of radiolabeled pep-
tides derived from gastrin and cholecystokinin families showed
anti-tumoral activity in xenograft models of medullary thyroid
cancer (85) [also extensively reviewed in Ref. (86)]. This means
that radiolabeled CCK or other compounds with high affinity for
CCK receptors could be useful for diagnosis (i.e., imaging) and
perhaps also for the treatment of Ewing sarcoma.
In summary, although high levels of CCK in Ewing sarcoma
tumorswere describedmore than twodecades ago, research in this
field has been scattered during the last years, and many questions
remain unresolved. For example, it is not clear enough what
type of CCK receptors are expressed in Ewing sarcoma tumors
or the mechanism and intracellular signaling pathways involved
in CCK-mediated cell proliferation. Any progress in this regard
would help to develop molecules capable of interfering with this
autocrine loop (Figure 5).
LOX
Lysyl oxidase (LOX) (protein lysine-6-oxidase; EC 1.4.3.13) is
a member of a family of lysyl oxidases that share the enzyme
catalytic domain. This family includes LOX and the LOX-like pro-
teins LOXL1 to 4. These enzymes catalyze lysine-derived covalent
crosslinking of collagen and elastin and therefore their function
is key for maintaining the structural integrity of the extracellular
matrix [extensively reviewed in (87–90)]. LOX is synthesized as a
50-KDa inactive proenzyme (preLOX), which is secreted to the
extracellular environment where it is proteolytically processed
into a functional 32-KDa LOX enzyme and an 18-KDa propep-
tide (LOX-PP). Together with the critical role that LOX plays in
maintaining the properties of the connective tissues, it has been
also shown to play important roles in cancer.
The first evidence of a relationship between LOX and can-
cer comes from experiments designed to identify genes involved
in Ras-mediated transformation of NIH-3T3 mouse fibroblasts
(91). Several functional experiments demonstrated that LOX had
properties that are characteristic of a suppressor gene. Thus, LOX
antisense cDNAwas able to retransformH-ras-transformed rever-
tants (92) and confer tumorigenic features to normal rat kidney
fibroblasts (NRK-49F) (93).
Since LOX is proteolytically processed into a fragment con-
taining the lysyl oxidase enzymatic activity and an N-terminal
propeptide (LOX-PP), experiments were conducted to determine
in which of these fragments resided the tumor suppressor activity.
Thus, Palamakumbura et al. described for the first time that
recombinant LOX-PP was able to inhibit neoplastic transfor-
mation features in Ras-transformed mouse fibroblasts such as
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FIGURE 5 | CCK and therapeutic opportunities in Ewing sarcoma. CCK is
an EWS/FLI1 target gene and its expression is elevated in Ewing sarcoma cells.
Functionally, inhibition of CCK expression impairs growth and migration in Ewing
sarcoma cells. It still remains to be addressed if CCK is a direct EWS/FLI1 target
or not (1) and which is the exact signaling pathway that takes place once CCK
binds to its receptors in the cells (2). Also it is still unknown whether CCK binds
exclusively to its canonical CCKRs or if there are other receptors (3) or even if it
can enter directly into the cell through some yet unknown mechanism (4).
Therapeutically, it may be interesting to further test receptor antagonists other
than devazepide (D) that could interfere with CCK binding to its receptors in
Ewing sarcoma cells (5). Also, from a diagnosis point of view, it could be useful
to test radiolabeled CCK derivatives (CCKd) to be used in imaging technologies
(6). All in all, more studies are needed to define the principal components and
pathways that are involved in the CCK-autocrine loop.
growth in anchorage independent conditions and Ras-dependent
induction of NFκB (94). Currently, numerous studies support
that the tumor suppressor activity of LOX resides in the 18-kDa
propeptide fragment LOX-PP and not in the lysyl oxidase enzyme.
In agreement with its tumor suppressor activity, LOX expres-
sion has been reported to be downregulated in many different
types of human cancer, such as fibrosarcoma, rhabdomyosar-
coma, and melanoma cells (95), lung (96), pancreatic cancer (97),
prostate (98), and colorectal cancers (99), which means that LOX
expression levels negatively correlate with malignant transfor-
mations. By contrast, LOX expression has been also reported
to be increased in a number of human cancers [i.e., breast and
colon carcinomas (100, 101)] particularly in the metastatic and
more aggressive forms of the disease. Interestingly, in these cases,
metastatic and invasive properties have been related to the lysyl
oxidase activity of LOX, rather than to LOX-PP (100, 101).
The anti-tumor activity of LOX-PP has been demonstrated in
various types of tumor cells although the mechanism underly-
ing the tumor suppressor activity of LOX-PP still needs to be
clarified. Data obtained until now indicate that LOX-PP can act
at different levels, and that the pathways and functions affected
can depend of the cancer or cell model studied. For example, in
Her-2/neu-transformedNF639 breast cancer cells, ectopic expres-
sion of LOX-PP interferes with fibronectin-stimulated tyrosine
phosphorylation of cellular proteins involved in integrin signal-
ing, inactivating the focal adhesion kinase (FAK), and conse-
quently diminishes the migratory response (102). In other breast
cancer cells driven by Her-2/neu (ERBB2), LOX-PP expression
suppressed AKT, ERK, and NFκB activation, as well as cell migra-
tion, growth in soft agar and tumor formation in nude mice
(103). Moreover, in cells derived from prostate cancer (DU145
and PC-3), LOX-PP blocks FGF-2 binding to the cell, inhibit-
ing MAPK/ERK and PI3K/Akt pathways and blocking serum-
stimulated DNA synthesis and cell proliferation (104). On the
other hand, LOX-PP decreased the levels of NF-κB and cyclin
D1 in Her-2/neu-transformed NF639 breast cancer cells and
MIA PaCa-2 pancreatic cancer cells, together with a reduction
in migration and growth in soft agar (105). Finally, in PANC-1
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pancreatic cancer cells, LOX-PP also impaired AKT and ERK
activity and growth in soft agar and cell migration (97).
Recently, a connection between LOX and Ewing sarcoma
pathogenesis has been also demonstrated. Thus, EWS/FLI1
knockdown in Ewing sarcoma cells induces the expression of LOX
indicating that this gene is strongly repressed by EWS/FLI1 in
these cells (15). An independent study showed that LOX is a direct
target of EWS/FLI1 by using ChIP assays (106). In agreement with
this, LOX expression was found to be low or undetectable in a
group of Ewing sarcoma cell lines and primary tumors (15). Since
these data suggested that LOX could act as a tumor suppressor
in Ewing sarcoma, functional studies were carried out. Thus,
ectopic expression of LOX-PP in the A673 Ewing sarcoma cell
line reduced cell proliferation, cell migration, anchorage inde-
pendent growth, and impaired tumor growth in vivo, indicating
that it had tumor suppressor activities in this cell, in line with
what was observed in other tumors. By contrast, the mature LOX
enzyme displayed the opposite effects. Interestingly, when full-
length LOX, including LOX enzyme and LOX-PP activities was
expressed in A673 cells, the anti-tumor effects prevailed (15).
Altogether, these studies indicate that LOXplays an important role
in Ewing pathogenesis by acting as a tumor suppressor gene.
The mechanisms involved in LOX-PP-mediated suppression in
Ewing sarcoma have only been partially studied. In one study,
ectopic expression of LOX-PP showed to impair ERK signaling
pathway, whereas the PI3K/AKT pathway remained unaffected
(15). Interestingly, in this work, an analysis of the gene expression
profile induced by LOX-PP expression in the A673 Ewing cell
line showed that a significant proportion of the genes affected
belonged to pathways involved in cell proliferation and cell cycle
control. Given the impact that LOX-PP expression has on tumori-
genesis, it is necessary to extend these studies in order to char-
acterize in more detail the pathways that may be affected by the
exposition of Ewing sarcoma cells to LOX-PP, and particularly
to determine which specific growth factor pathways could be
affected by LOX-PP.
Other interesting aspect that remains to be determined is the
identification of the proteins that interact with LOX-PP in Ewing
sarcoma cells. In other cell types, LOX-PP has been shown to
interact with a number of proteins such as Hsp70, c-Raf or CIN85
(107), so it would be interesting to identify and characterize LOX-
PP partners in the specific Ewing sarcoma cell context and to
elucidate their role in LOX-PP mediated tumor suppression.
The fact that LOX-PP acts as a tumor suppressor gene in
cancer, and specifically in Ewing sarcoma, invites to assess the
therapeutic value of LOX-PP. The easiest strategy is to evaluate
the effect of the administration of LOX-PP on tumor cells. Thus,
recombinant LOX-PP has been used to ascertain its therapeutic
potential in several cancer types both in vitro and in vivo (94,
97, 102–105, 108, 109). In all cases, exogenous LOX-PP reduced
tumor cells growth, supporting the therapeutic usefulness of this
strategy. Interestingly, in one study, the combination of LOX-
PP with the chemotherapeutic agent doxorubicin in breast and
pancreatic cancer cells in vitro showed an enhanced cytotoxic
effect of doxorubicin when the cells were first sensitize by incu-
bation with LOX-PP (105). These results mean that even if LOX-
PP is not capable of inducing complete cell death by itself, it
could potentially sensitize cancer cells to standard therapies thus
allowing to lower the doses and adverse side effects associated
to conventional chemotherapy and radiotherapy. At the moment,
there are no data about the effect of exogenous administration of
LOX-PP, alone or in combination with chemotherapeutic drugs,
on Ewing sarcoma cells. These preclinical studies are therefore
needed to test if this strategy can represent a promising line of
research in order to find new therapeutic approaches to treat
Ewing sarcoma patients.
Since LOX expression, and thus LOX-PP, is downregulated
in Ewing sarcoma cells by EWS/FLI1 (15, 106), other therapeu-
tic approach could be the induction of LOX expression, and
thus LOX-PP, in these cells. In this line, it has been proposed
that EWS/FLI1 binds to LOX promoter and downregulates LOX
expression by recruiting the NuRD transcriptional repressor com-
plex containing the HDACs and LSD1 associated proteins. Inter-
estingly, the use of HDACs inhibitors (vorinostat/SAHA) or LSD1
inhibitors (HCI-2509) induced an increase in the levels of LOX
mRNA in A673 Ewing sarcoma cells, which suggest that the anti-
tumor effect of these drugs could be mediated, at least in part,
by the upregulation of LOX (106). However, induction of LOX
expression to achieve an increased production of anti-tumorigenic
LOX-PP in Ewing sarcoma cells may not be as beneficial as
expected: while induction of LOX expression would cause an
increase in LOX-PP, it also would produce an increase in the
production of the LOX mature enzyme, which has been showed
to be pro-oncogenic in Ewing sarcoma cells and other tumors (15,
100, 101).
Other opportunities for therapeutic interventions could be
derived from the identification and characterization of LOX-
PP interactions with other proteins, mainly intracellular proteins
involved in cell signaling and regulation of tumorigenic processes.
Biochemical studies have shown that LOX-PP is an intrinsically
disordered protein (110). These proteins are expected to par-
ticipate in signaling processes due to their capability to adopt
interconverting structures and to interact with their partners, and
have been proposed to be potential drug targets (111). Thus,
characterization of the exact motifs that are involved in LOX-PP
interactions can open the door to the identification of targetable
proteins and the design of small molecules capable to reproduce
the effect of LOX-PP.
In summary, LOX, and more specifically LOX-PP, has been
showed to have anti-tumorigenic properties, which could be
exploited to treat cancer cells. Regarding Ewing sarcoma, it is
yet more than necessary to characterize the pathways involved in
LOX-PP mediated tumor-suppression, in particular the identifi-
cation of the protein interactions that mediate this response, in
order to identify key factors that could provide new therapeutic
targets (Figure 6).
Conclusion
Ewing sarcoma is driven by EWS/FLI1, which is a protein gener-
ated by a tumor-specific aberrant translocation. Although it may
seem like a perfect target for therapeutic applications, directed
therapies toward it have failed to reach the clinic (112). For this
reason, the identification of EWS–FLI target genes and their role
in tumor signaling networks have been addressed in the last years,
and some excellent reviews have assessed this topic (4, 113, 114).
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FIGURE 6 | LOX and therapeutic opportunities in Ewing sarcoma.
LOX expression is repressed by EWS/FLI1 in Ewing sarcoma cells.
Functional studies have demonstrated that LOX acts as a tumor suppressor
gene in Ewing sarcoma and that its activity resides in its propeptide domain
(LOX-PP). Therapeutic opportunities could include for example (1) LOX
de-repression by targeting repression complexes that interact with
EWS/FLI1 at the LOX promoter, (2) administration of LOX-PP or LOX-PP
active derived peptides to block ERK signaling alone or in combination with
traditional chemotherapy (3) or blocking the LOXenz fraction activity (4). The
mechanisms through which LOX-PP exerts its anti-tumor activity are largely
unknown, especially in Ewing sarcoma. For instance, it is currently unknown
if LOX-PP specific receptors (5) (intracellular or transmembrane) are
necessary to produce its anti-tumor activities or if the different
LOX-PP-interacting proteins may interfere with its activity in Ewing sarcoma
(6). Any advance in these aspects could provide new clues to design new
therapeutic tools.
This review is focused on the EWS/FLI1 downstream regula-
tory network, particularly on EWS/FLI1 up- and down-regulated
target genes on which the study of potential targeted therapies
could be of clinical interest. Also, we stated some current questions
regarding pathways and unknown mechanisms underlying the
functional effects of these genes in Ewing sarcoma that still remain
unresolved and could help find key clues for the future studies of
this disease. There are plenty of mechanisms regarding EWS/FLI1
target genes that are still unknown and a deeper knowledge on
them could potentially lead to the development of more specific
and less toxic therapies in Ewing sarcoma.
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